Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions

Arrowhead Pharmaceuticals, Inc. was represented by Gibson Dunn in concurrent public offerings of convertible notes, common stock, and pre-funded warrants to buy common stock for a total gross proceeds of $930 million, as well as capped call transactions pertaining to the convertible notes.